Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa - Maiza, J C; Vezzosi, D; Matta, M; Donadille, F; Loubes-Lacroix, F; Cournot, M; Caron, P (Clin Endocrinol, 2007)
Bennet